Utility of Integrated Analysis of Pharmacogenomics and Pharmacometabolomics in Early Phase Clinical Trial: A Case Study of a New Molecular Entity by Jaeseong Oh, Sojeong Yi, Namyi Gu, Dongseong Shin, Kyung-Sang Yu, Seo Hyun Yoon, Joo-Youn Cho, In-Jin Jang

“…In this report, we present a case study of how pharmacogenomics and pharmacometabolomics can be useful to characterize safety and pharmacokinetic profiles in early phase new drug development clinical trials. …”
Get full text

Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomize... by Binghe Xu, Qingyuan Zhang, Yang Luo, Zhongsheng Tong, Tao Sun, Changping Shan, Xinlan Liu, Yumin Yao, Bing Zhao, Shusen Wang, Xiaohua Zeng, Changlu Hu, Xi Yan, Xiaojia Wang, Hongyan Jia, Zhendong Chen, Fuming Qiu, Xinhong Wu, Deyong Zhang, Tong Li

“…The secondary endpoints included PFS assessed by Blinded Independent Central Review (BICR), objective response rate (ORR), duration of response (DOR), disease control rate (DCR), clinical benefit rate (CBR), overall survival (OS), safety and tolerability and pharmacokinetic profile. DOR is not reported, and OS data was immature at the data cut-off but unplanned ad hoc analysis is reported. …”
Get full text

The potential of Curcuma longa L. bioactive compounds as RSK inhibitors for the treatment of prostate cancer: in silico study by Olusola Olalekan Elekofehinti, Foluso Adeola Taiwo, Moses Orimoloye Akinjiyan, Ifeoluwa Rachael Adetoyi, Folasade Oluwatobiloba Ayodeji, Adedotun Olayemi Oluwatuyi, Oluwapelumi Nifesimi Akintoye, Idayat Oyinkansola Kehinde, Bolanle Esther Adedapo, Opeyemi Iwaloye

“…Results Five bioactive compounds may be possible lead drugs for the treatment of prostate cancer because they have the lowest binding energies, ranging from − 9.0 kcal/mol to − 11.00 kcal/mol, and have better pharmacokinetic qualities than the standard drugs docetaxel, enzalutamide, and abiraterone. …”
Get full text

Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients by Alan D. Kaye, Shivam S. Shah, Coplen D. Johnson, Adalyn S. De Witt, Austin S. Thomassen, Charles P. Daniel, Shahab Ahmadzadeh, Sridhar Tirumala, Kristin Nicole Bembenick, Adam M. Kaye, Sahar Shekoohi

“…Emerging tools, including dried blood spot sampling and pharmacokinetic modeling, offer innovative methods to simplify monitoring and enhance precision in outpatient settings. …”
Get full text

Chemical, Spectral, Biological, and Toxicological Studies of Some Benzene Derivatives Used in Pharmaceuticals: In Silico Approach by Emranul Kabir, M R O Khan Noyon, Md Rabiul Alam, Mr. Nasiruddin, Sajia Islam, Mahima Akter, Monir Uzzaman

“…All derivatives were predicted by ADMET to have improved pharmacokinetic properties and less acute oral toxicity. …”
Get full text

GC1126A, a novel ADAMTS13 mutein, evades autoantibodies in immune-mediated thrombotic thrombocytopenic purpura by Heechun Kwak, Gahee Choi, Suyong Kim, Ji-Min Park, Youngeun Kwon, Yongmin Lee, Chaemok Lee, Shangbin Yang, Spero Cataland, Sunghyun Kim, Soo-Mee Bang, Jae-Ho Yoon, Wooin Lee, Hyun-Ja Nam

“…The selected muteins were assessed for pharmacodynamic biomarkers and pharmacokinetic profiles in the iTTP-mimic and wild-type mice, respectively. …”
Get full text

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC by Francesca Lucibello, MD, Valérie Gounant, MD, PhD, Mihaela Aldea, MD, PhD, Michaël Duruisseaux, MD, PhD, Maurice Perol, MD, Christos Chouaid, MD, Jaafar Bennouna, MD, PhD, Vincent Fallet, MD, Aldo Renault, MD, Florian Guisier, MD, PhD, Etienne Giroux-Leprieur, MD, PhD, Marie Wislez, MD, PhD, Anne-Claire Toffart, MD, PhD, Julien Mazieres, MD, PhD, Clémence Basse, MD, PhD, Nadia Hegarat, PhD, Matthieu Carton, MD, Nicolas Girard, MD, PhD

“…Pralsetinib was administered at a daily dose of 400 mg based on safety and pharmacokinetic outcomes from previous phase 1/2 study. …”
Get full text

Bioadhesive Chitosan Films Loading Curcumin for Safe and Effective Skin Cancer Topical Treatment by Seila Tolentino, Mylene M. Monteiro, Felipe Saldanha-Araújo, Marcilio Cunha-Filho, Tais Gratieri, Eliete N. Silva Guerra, Guilherme M. Gelfuso

“…<b>Background/Objectives</b>: This study aimed to evaluate the safety and efficacy of chitosan-based bioadhesive films for facilitating the topical delivery of curcumin in skin cancer treatment, addressing the pharmacokinetic limitations associated with oral administration. …”
Get full text

Power-free plasma separation based on negative magnetophoresis for rapid biochemical analysis by Lin Zeng, Chao Liu, Yi Yang, Shi Hu, Ruihan Li, Xiaotian Tan, Jienan Shen, Yi Zhang, Shaohui Huang, Hui Yang

“…The separated plasma proved effective for subsequent analysis of antibody concentration and size in the separated plasma for pharmacokinetic investigations, yielding results on par with those obtained via centrifugation. …”
Get full text

In vivo production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection by Yuta Suzuki, Takayuki Miyazaki, Yoko Ida, Tatsuya Suzuki, Yumi Itoh, Shuto Nakao, Keita Kondo, Kenji Kubara, Keisuke Nishioka, Hiroki Muto, Ryuji Watari, Toshifumi Hirayama, Dai Kakiuchi, Shinya Sato, Satoshi Inoue, Yoshifumi Uemoto, Yohei Mukai, Atsushi Hoshino, Toru Okamoto, Junji Matsui

“…Systemic delivery of mRNA in mice resulted in a dose-dependent expression of 3N39v4 in plasma (20–261 μg/mL at 1–10 mg/kg) with sufficient tolerability. An improved pharmacokinetic profile of the produced protein was compared to injection of the 3N39v4 protein. …”
Get full text

Radiopharmaceuticals and their applications in medicine by Siqi Zhang, Xingkai Wang, Xin Gao, Xueyao Chen, Linger Li, Guoqing Li, Can Liu, Yuan Miao, Rui Wang, Kuan Hu

“…These include high tumor uptake, prolonged retention time, and favorable pharmacokinetic properties that align with clinical standards. …”
Get full text

Enhancement of Cognitive Benefits and Anti-Anxiety Effects of <i>Phytolacca americana</i> Fruits in a Zebrafish (<i>Danio rerio</i>) Model of Scopolamine-Induced Memory Impairment by Lucia-Florina Popovici, Ion Brinza, Florentina Gatea, Georgiana Ileana Badea, Emanuel Vamanu, Simona Oancea, Lucian Hritcu

“…In silico analyses were performed to evaluate the pharmacokinetic characteristics of the phenolic compounds discerned in the two extracts, using platforms such as SwissAdme, Molinspiration, ProToX-III, AdmetLab 3.0, PKCSM, and PASS. …”
Get full text

The use of triptans as an effective form of migraine treatment – review by Agata Borkowska, Anna Kiełb, Anna Mich, Anna Kaźmierczak, Patrycja Sornek, Wiktoria Izdebska, Igor Pawlak, Radosław Ciesielski, Jakub Stanek, Klaudia Perkowska

“…Differences in triptan medications' onset and half-life affect their therapeutic duration and headache recurrence rate. The pharmacokinetic properties of each triptan significantly affect its efficacy and headache recurrence likelihood. …”
Get full text

Safety and recommendation of voriconazole for invasive pulmonary aspergillosis in severe liver disease patients: a retrospective cohort study by Xin Zhang, Caopei Zheng, Ling Zhang, Yuqing Sun, Ying Liang, Xue Chen, Lijun Pang, Yulin Zhang

“…A no-loading dose voriconazole regimen is proposed for IPA treatment in SLD patients, yet pharmacokinetic studies combined with prospective studies are needed for further validation.…”
Get full text

Development and Optimization of Nano-Hydroxyapatite Encapsulating Tocotrienol-Rich Fraction Formulation Using Response Surface Methodology by Anis Syauqina Mohd Zaffarin, Shiow-Fern Ng, Min Hwei Ng, Haniza Hassan, Ekram Alias

“…However, its application is limited due to its poor oral bioavailability profile, warranting an innovative approach to overcome its pharmacokinetic limitations. Recently, the nano-hydroxyapatite (nHA) has been investigated as a drug delivery vehicle for various drugs and active compounds owing to its excellent biocompatibility, biodegradability, and osteogenic properties. …”
Get full text

L-Citrulline in Neonates: From Bench to Bed Side by Dwayne Mascarenhas, Atefeh Mohammadi, Randa Higazy, Julijana Ivanovska, Estelle Gauda, Bonny Jasani

“…Similar benefits were noted in newborn piglet models of chronic hypoxia-induced PH and NEC. Pharmacokinetic studies in neonates have shown doses of 100–300 mg/kg/day to be safe and well tolerated. …”
Get full text

Neuroprotective Potential of <i>Origanum majorana</i> L. Essential Oil Against Scopolamine-Induced Memory Deficits and Oxidative Stress in a Zebrafish Model by Ion Brinza, Razvan Stefan Boiangiu, Iasmina Honceriu, Ahmed M. Abd-Alkhalek, Samir M. Osman, Omayma A. Eldahshan, Elena Todirascu-Ciornea, Gabriela Dumitru, Lucian Hritcu

“…In parallel, we performed in silico predictions (research conducted using computational models) of the pharmacokinetic properties of the main compounds identified in OmEO, using platforms such as SwissADME, pKCSM, ADMETlab 2.0, and ProTox-II. …”
Get full text

Unveiling the toxicity of JWH-018 and JWH-019: Insights from behavioral and molecular studies in vivo and vitro by Fenghua Zhou, Yan Shi, Sujun Tan, Xiaoli Wang, Weicheng Yuan, Shuqi Tao, Ping Xiang, Bin Cong, Chunling Ma, Di Wen

“…In the present study, we aimed to investigate the toxicity and underlying mechanisms of indole SCs JWH-018 and JWH-019 in mice (C57BL/6, male, 6–8 weeks old), zebrafish (AB strain, male, 4–5 months old) and modified human embryonic kidney (HEK) 293 T cells, using behavioral, pharmacokinetic, pharmacological approaches, and molecular docking. …”
Get full text

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial by Jeffrey M. Clarke, George R. Simon, Hirva Mamdani, Lin Gu, James E. Herndon, Thomas E. Stinchcombe, Neal Ready, Jeffrey Crawford, Guru Sonpavde, Stephen Balevic, Andrew B. Nixon, Michael Campa, Elizabeth B. Gottlin, Huihua Li, Ruchi Saxena, You Wen He, Scott Antonia, Edward F. Patz

“…Stable disease occurred in 9 patients (29%) and the median overall survival was 25.7 weeks (95% confidence interval [CI], 19.1–30.6). Pharmacokinetic analysis confirmed an estimated half life of 6.5 days. …”
Get full text

Chemometric Methods—A Valuable Tool for Investigating the Interactions Between Antifungal Drugs (Including Antifungal Antibiotics) and Food by Agnieszka Wiesner-Kiełczewska, Paweł Zagrodzki, Alicja Gawalska, Paweł Paśko

“…We constructed PLS models with changes in the pharmacokinetic parameters (∆AUC, area under the curve; ∆C_max, maximum drug concentration; and ∆T_max, time to reach maximum drug concentration) after dietary intervention as the response parameters and eight groups of molecular descriptors (M1–M8) as the predictor parameters. …”
Get full text